Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012

Bone

Volumn 57, Issue 2, 2013, Pages 423-428

  Wysowski, Diane K ^a   Greene, Patty ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Alendronate; Bisphosphonates; Ibandronate; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GENERIC DRUG; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; ASIAN; BODY MASS; CAUCASIAN; DRUG MARKETING; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PRESCRIPTION; TREND STUDY; UNITED STATES;

ALENDRONATE; BISPHOSPHONATES; IBANDRONATE; OSTEOPOROSIS; RISEDRONATE;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; HEALTH SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MARKETING; MIDDLE AGED; OSTEOPOROSIS; PHYSICIANS; UNITED STATES; YOUNG ADULT;

EID: 84885217290     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.09.008     Document Type: Article

References (29)

1. Cummings S.R., Kelsey J.L., Nevitt M.C., O'Dowd K.J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985, 7:178-208.
2. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443. Alendronate Phase III Osteoporosis Treatment Study Group.
3. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541. Fracture Intervention Trial Research Group.
4. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
5. Solomon D.H., Rekedal L., Cadarette S.M. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009, 21:363-368.
6. Maconi G., Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995, 90:1889-1890.
7. Ribeiro A., DeVault K.R., Wolfe J.T., Stark M.E. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998, 47:525-528.
8. Abraham S.C., Cruz-Correa M., Lee L.A., Yardley J.H., Wu T.-T. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999, 12:1152-1157.
9. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
10. Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V. Oral bisphosphonates and risk of cancer of the esophagus, stomach, and colorectum: nested case-control study. BMJ 2010, 341:c4444. 10.1136/bmj.c4444.
11. Wysowski D.K., Chang J. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165:346-347.
12. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. For the HORIZON Recurrent Fracture Trial, zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
13. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Egroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
14. Lo J.C., O'Ryan F.S., Gordon N.P., Yang J., Hui R.L., Martin D., et al. Predicting risk of osteonecrosis of the jaw with oral bisphosphonate exposure (PROBE) Investigators. J Oral Maxillofac Surg 2010, 68:243-253.
15. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
16. Heckbert S.R., Li G., Cummings S.R., Smith N.L., Psaty B.M. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
17. Goh S.-K., Yang K.Y., Koh J.S.B., Wong M.K., Chua S.Y., Chua D.T.C., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg 2007, 89-B:349-353.
18. Warren C., Gilchrist N., Coates M., Frampton C., Helmore J., McKie J., et al. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review. ANZ J Surg 2012, 10.1111/j.1445-2197.2012.06199.x.
19. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
20. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
21. Black D.M., Bauer D.C., Schwartz A.V., Cummings S.R., Rosen C.J. Continuing bisphosphonate treatment for osteoporosis - for whom and how long?. N Engl J Med 2012, 366:2051-2053.
22. Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphonates for osteoporosis - where do we go from here?. N Engl J Med 2012, 366:2048-2051.
23. Fosamax (alendronate sodium) drug information: indications, dosage, and how supplied [Accessed April 10, 2013]. http://www.rxlist.com/fosamax-drug/indications-dosage.htm.
24. IMS Health Vector One® National (VONA), 2002-2012 2013, [Data extracted February, April, and August].
25. IMS Health Vector One® Total Patient Tracker, 2002-2012 2013, [Data extracted April].
26. IMS Health National Sales Perspectives, TM 2002-2012 2013, [Data extracted February].
27. Encuity Research. Treatment Answers, TM 2002-2012 2013, [Data extracted February].
28. Moeny D. Briefing information for the September 9, 2011 Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee 2013, 161. [Appendix 8, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf Accessed April 22, 2013].
29. Burden A.M., Paterson J.M., Solomon D.H., Mamdani M., Juurlink D.N., Cadarette S.M. Bisphosphonate prescribing, persistence, and cumulative exposure in Ontario, Canada. Osteoporos Int 2012, 23:1075-1082.